PR Newswire Asia's news > Medical/Pharmaceuticals

 < Previous page   |   Title only   |   Print    Next page > 
     
The Next Chapter of B7-H3: From Systemic Disease to the Brain
Early Data for T-MAXIMUM's B7-H3 Allogeneic CAR-T in Brain Metastases Presented at WCLC 2026 ...
2026-09-21T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
WuXi XDC Celebrates GMP Release of Singapore Site, Ushering in a New Era of Global Expansion
SINGAPORE , Sept. 21, 2026 /PRNewswire/ --WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused ...
2026-09-21T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Neuralli™ MP Goes Global: US Probiotic Medical Food Meets Singapore HSA Notification
Milestone Builds on Hong Kong's Healthcare Professionals Choice Probiotic Award and Full US HSA/FSA Payment Eligibility ...
2026-09-21T    Health Care/Hospital   Medical/Pharmaceuticals 
6 countries across Terumo Asia Pacific officially recognized as Best Workplaces™ Certified by Great Place To Work®
SINGAPORE , Sept. 21, 2026 /PRNewswire/ -- Terumo is proud to announce that 6 countries across Terumo Asia Pacific have officially been recognized as Best Workplaces ™ Certified by Great Place To ...
2026-09-21T    Banking/Financial Service   Health Care/Hospital   Medical Equipment   Medical/Pharmaceuticals 
MALAYSIA HEALTHCARE DEEPENS BANGLADESH PRESENCE AS MEDICAL TOURISM DEMAND GROWS
CHATTOGRAM, Bangladesh , Sept. 21, 2026 /PRNewswire/ -- Malaysia Healthcare Travel Council (MHTC) deepened its engagement in Bangladesh through Malaysia Healthcare Week in Bangladesh, held from 16 to ...
2026-09-21T    Health Care/Hospital   Medical/Pharmaceuticals   Trade show news 
Telix and ITM Join Forces to Create a Radiopharmaceutical Powerhouse
Transformational merger reinforces Telix's long-term growth strategy as a vertically integrated radiopharmaceutical company with enhanced capabilities across development, isotope production and global ...
2026-09-21T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Antengene Announces First Patient Dosed in Pivotal Phase III CLINCH-3 Study of ATG-022
SHANGHAI and HONG KONG , Sept. 21, 2026 /PRNewswire/ -- Antengene Corporation Limited ( "Antengene" , SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated ...
2026-09-21T    Biotechnology   Health Care/Hospital   Medical Equipment   Medical/Pharmaceuticals 
Specialised Therapeutics Expands Partnership with Incyte to Include Ruxolitinib Cream (Opzelura®) in Australia
SINGAPORE , Sept. 21, 2026 /PRNewswire/ -- Independent biopharmaceutical company Specialised Therapeutics (ST) today announced an expansion of its existing partnership with Incyte Biosciences International, ...
2026-09-21T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
JACC: Clinical Electrophysiology Publishes 12-Month Outcomes from Field Medical's First-in-Human Field PULSE Trial: 94.2% Per-Vein PVI Durability with Optimized Waveform
Late-breaking HRX data advance Field Medical's "instantaneous ablation" workflow and expand the clinical evidence for high-voltage focal PFA with the FieldForce™ PFA System ...
2026-09-20T    Health Care/Hospital   Medical Equipment   Medical/Pharmaceuticals 
S2S China Announces 2026 Finalists, Ten Standout Teams Set to Pitch Global Investors at Westlake University
SHANGHAI, Sept. 20, 2026 /PRNewswire/ -- The inaugural S2S China Symposium has announced the finalists of its 2026 program. Co-hosted by RA Capital Management and Qiming Venture Partners, S2S China ...
2026-09-20T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
 < Previous page    Next page >

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2026 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.